Objective: The perimenopausal increase in circulating dehydroepiandrosterone sulfate (DHEAS) levels during the menopausal transition (MT) is accompanied by other adrenal steroids that have the potential to alter estrogen/ androgen balance and explain the wide interwoman range of estrogen-related symptoms experienced during the MT.
A gradual decrease in ovarian function is usually invoked to explain many of the symptoms, such as hot flashes, that are associated with the menopausal transition (MT). However, finding a simple and satisfactory explanation for the specific timing of onset of symptoms and the inability to demonstrate a lack of correlation of circulating hormones to the severity of symptoms have been challenging, based on the observed between-woman similarity in circulating estradiol (E 2 ) through most of the MT. Despite this similarity in circulating E 2 , only some perimenopausal and postmenopausal women become clinically estrogen deficient during and after menopause, whereas others require estrogen replacement.
Hormone levels in longitudinal blood samples collected in the early follicular phase of the menstrual cycle indicate that circulating E 2 levels fall modestly during the early and earlylate perimenopause then decline more rapidly during the 2 years just before and immediately after menopause.
1 E 2 levels decline to their lowest circulating concentration 2 years after menopause. 2 Circulating testosterone (T) levels tend to follow the same timing and trajectory as E 2 levels before menopause. 3 Circulating follicle-stimulating hormone levels begin to rise several years before any detected fall in circulating E 2 levels, and sex hormoneYbinding globulin (SHBG) concentrations gradually decline during the 3 years just before menopause. 1 In contrast with ovarian steroid hormones, there is an increase in adrenal dehydroepiandrosterone sulfate (DHEAS) levels that begins during early perimenopause and plateaus at menopause. 4 This rise in DHEAS (from 108 to 112 Kg/dL, P = 0.0027) has been shown to occur in 85% of women and represents increased adrenal steroidogenesis because it is observed in women who have undergone bilateral salpingooophorectomy. 5 If this increase in adrenal steroidogenic activity during the MT includes downstream steroids in the $-5 steroidogenic pathway, particularly 5-androstene-3A,17A-diol (Adiol), then such a general increase could contribute to the estrogen/androgen ratio because Adiol has both estrogenic and androgenic biological properties. 6, 7 Increased circulating Adiol may therefore be important before and immediately after menopause, when circulating E 2 levels undergo the most precipitous decline. In addition, if the wide interwoman range of adrenal steroid production observed during the MT includes Adiol, then this wide range of potential estrogenic complements may help explain the wide range of symptoms observed at this time.
The current dogma indicates that the peripheral conversion of prohormones such as dehydroepiandrosteone (DHEA) progressively compensates for the decreased production of steroid hormones from the ovary as perimenopause progresses. However, recent data 3, 4 suggest that an increase in the direct secretion of Adiol, androstenedione (Adione), and T may be equally important to the availability of substrates for 17A-hydroxysteroid dehydrogenase and aromatase. Therefore, the measurement of the circulating concentrations of adrenal steroids, particularly Adiol with its estrogenic potential, may provide a more appropriate indicator of hormone balance before and after menopause.
There is growing evidence that the rise in adrenal C-19 steroids may dominate the perimenopause steroid hormone profiles and influence the incidence of symptoms as well as the course of health trajectories. With this in mind, the present study was conducted to document the rise of four C-19 adrenal steroids during the MT and to characterize each of their biological potentials.
METHODS
This study reports results from annual serum samples obtained from the overall Study of Women's Health Across the Nation (SWAN) population, which has been previously described. 8 Briefly, SWAN is a multisite longitudinal cohort study that was conducted in community-based groups of women who belonged to one of five ethnic/racial groups. Eligibility criteria for the SWAN longitudinal cohort were age of 42 to 52 years, intact uterus and at least one ovary, no current use of estrogens or other medications known to affect ovarian function, at least one menstrual period in the 3 months before screening, and selfidentification in one of five eligible ethnic groups. Institutional review board approval was obtained at each study site.
A selection of serum samples (n = 144) from the SWAN collections was based solely on the concentration of DHEAS during the MT to capture the full range of values in the steroids secreted in concert with DHEAS. The samples selected (Table 1) represented equal numbers for the following groups (n = 36 for each group): greater than 1 SD above the mean DHEAS concentration (group A); between the mean and 1 SD above the DHEAS mean (group B); between the mean and 1 SD below the DHEAS mean (group C); lower than 1 SD below the DHEAS mean (group D). Samples were chosen so that they represent the complete range of DHEAS concentrations (Fig. 1) . Ethnicity, body mass index, menopause status, or other demographic characteristics were not considered in the selection of samples, only DHEAS concentration. This selection was based on the concept that the rise in DHEAS is common among women and that Adiol-circulating concentrations would be strongly correlated to DHEAS and a full range of Adiol concentrations would be captured. These four groups were further divided into the upper and lower halves of the E 2 concentrations within each group (n = 18). The eight groups permitted the estimate of the adrenal contribution to the estrogen receptor-> ligand load (ERLL) and androgenic bioactivity (androgen receptor [AR] ligand) when adrenal steroids, using DHEAS as a surrogate, were complementing circulating E 2 . All samples were frozen (j80-C) upon collection during the past 10 years. They had been thawed once previous to this study.
Assay methodology
DHEAS, T, and E 2 were measured using competitive chemiluminescent immunoassays on the Bayer Diagnostic ACS-180 automated analyzer as reported previously. 9 The interassay coefficients of variations are shown for the various assays in Table 2 , and additional details can be found in the supplemental materials (See Appendix, Supplemental Digital Content 1, http://links.lww.com/MENO/A16). Adione and Adiol were analyzed in serum by radioimmunoassay with preceding organic solvent extraction and Celite column chromatography steps. 10, 11 The E 2 assay is a semiautomated competitive immunoassay with manual steps and an offline incubation. Bioactive androgens were measured with an androgen signal transduction assay, using a human embryonic kidney cell line, stably cotransfected with human AR, and a luciferase reporter plasmid as previously reported. 12 We report the following: interassay and intra-assay coefficients of variation, 7.4% and 7.5%, respectively.
Bioactive estrogens were assessed as ERLLs in a stable signal transduction assay using human ovarian carcinoma cells that have been stably transfected with a luciferase reporter gene plasmid under the regulation of four estrogen response elements. These transfected human ovarian carcinoma cells were cultured in >-minimum essential medium with 10% fetal bovine serum (FBS). When the cells reached 80% confluence, they were trypsinized and well dispersed in phenol redYfree Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% dextran-coated charcoal strippped (DCC)-FBS. An equal number of cells at a density of 25,000 cells in 50 KL/well was then added to 96-well tissue culture plates containing 150 KL/well of phenol redYfree DMEM supplemented with 10% DCC-FBS. On each of the two subsequent days (days 2 and 3), the media in each well were removed and replaced with 200 KL of phenol redYfree DMEM supplemented with 10% DCC-FBS. On day 4, the media were again removed and replaced with 200 KL phenol redYfree DMEM supplemented with 10% DCC-FBS containing increasing concentrations of E 2 standards or sample sera. E 2 standards were dissolved in absolute alcohol and had a final alcohol content of 0.1% (vol/vol) to minimize any organic solvent effects. To compensate for any serum matrix effects, DCC-FBS was added to the E 2 standard preparation at a proportion equal to that of the serum content of the sample preparation (5% vol/vol). Serum samples were diluted in DCC-FBS with a final serum content of 5% (vol/vol). The plates were then incubated for an additional 18 hours. The media were removed, and 100 KL cell lysis buffer was added to each well and allowed to incubate for 20 minutes. Cell lysates (40 KL) were transferred to 96-well Microfluor II plates (Fisher Scientific, Santa Clara, CA). Luciferin substrate was injected into each well, and the luciferase activity induced by the standards and/or test serum was measured using a Veritas Luminometer (Turner Biosystems, Sunnyvale, CA). T, Adiol, and E 2 (Steraloids, Newport, RI) were measured as relevant dose responses in the same assay to determine their relative ERLL potency (Fig. 2) . We report the following: interassay and intra-assay coefficients of variation, 3.3% and 1.8%, respectively.
Data analysis
One-way analysis of variance was used to test whether Adione, Adiol, and T means differed by DHEAS groups. Spearman correlations and simple linear regression were used to test the strength and the direction of associations of circulating Adione, Adiol, and T levels with DHEAS as well as ERLL and AR with Adiol. Hormone values were log transformed before analysis. A P value of less than 0.05 was considered to be statistically significant. Data analysis was carried out using StatView Version 5.0.1.0 (1998, SAS Institute, Inc.) and SAS version 8.0.
RESULTS
The mean circulating concentrations of all adrenal androgens increase in concert with DHEAS, which had been reported previously.
3<5 Adiol (from 153 to 1,018 pg/mL) and DHEAS (from 35 to 283 Kg/dL) increased seven-and eightfold, respectively, whereas T (from 25 to 59 ng/dL) and Adione (from 556 to 1,216 pg/ml) increased twofold (Table 3) . DHEAS was positively correlated with T, Adione, and Adiol (linear regressions in Fig. 3 and Table 4 ). The correlation of DHEAS with Adiol was highest and was a little higher with Adione than with T. Adiol was consistently correlated with androgen bioactivity (linear regressions in Fig. 3 ), but, in general, it was not correlated with circulating estrogen bioactivity across the entire range of ERLL concentrations.
Circulating T was highly correlated with bioactive androgens throughout its range as previously described 12 (data not shown). Before menopause, SHBG concentrations declined and showed a modest positive correlation with E 2 (Q = 0.222) and negative correlation with T (Q = j0.113), whereas Adiol (Q = j0.067) and Adione (Q = j0.083) both showed weak negative correlations (data not shown).
Circulating Adiol concentrations were significantly correlated with bioactive estrogen concentrations (ERLL) only in the lowest quartile of E 2 and the highest quartile of adrenal steroids (Q = 0.38, P = 0.02) when compared with the mean of all correlations (Q = 0.016, P = 0.846). This correlation was weaker than the correlation between E 2 and ERLL (Q = 0.941, P e 0.0001), the mean of all correlations for all E 2 quartiles. The highest concentrations of E 2 showed an inhibition by the highest levels of Adiol, indicating that when E 2 is highest and presenting the greatest physiological impact, higher circulating levels of Adiol may reduce the effectiveness of E 2 by competing with E 2 for estrogen receptor (ER) binding.
The adrenal contribution to ERLL was evaluated by determining the ratio of the mean ERLL to the mean immunoreactive E 2 concentration in each of the eight groups of 18 samples described above (Table 5 ). ERLL and AR showed normal distributions within each group; therefore, we neither   FIG. 2 . The dose-response curves and molecular structures for E 2 , Adiol, DHEA, and T using a stably transfected cell line. The relative biological activity of each steroid was assessed using a cell-based signal transduction assay for ERLL. The concentration for each steroid is shown on the abscissa (M) and the signal transduction strength is shown on the ordinate in RLUs. RLU, relative light unit; E 2 , estradiol; Adiol, androstenediol; DHEA, dehydroepiandrosterone; T, testosterone; ERLL, estrogen receptor-> ligand load. The mean value, SD, and SEM of the hormones for each of the four groups of serum samples selected for hormone analysis as described in Figure 1 . Groups are significantly different when compared with the higher group. Highest E 2 is not significantly greater than the lowest E 2 . E 2 , estradiol; DHEAS, dehydroepiandrosterone sulfate; ERLL, estrogen receptor-> ligand load; AR, androgen receptor. log transformed nor used techniques of nonparametric analysis. In general, the ratios were 0.49 to 0.76, indicating that the numerator (estimate of bioactive E 2 + all other bioactive estrogens) was only slightly and consistently lower than the direct measure of total immunoreactive E 2 . In contrast, the ratio dropped to 0.64 and 0.49 (P G 0.02) in the group in which DHEAS concentrations were below 1 SD of the grand mean of DHEAS concentration. Because the portion of E 2 in the numerator was still the same as that in the denominator, this drop in the ratio indicates that the biologically active portion of non-E 2 estrogenicity was reduced when DHEAS and Adiol concentrations were low (Table 5) .
DISCUSSION
The rise in circulating DHEAS observed in most women during the MT is accompanied by a simultaneous rise in circulating T, Adione, and Adiol levels. This increase in adrenal androgens during the MT may be important by providing a reservoir of substrate for peripheral conversion into other bioactive steroids. In addition, an increase in bioactive androgens from a direct adrenal secretion may be equally, if not more, important than peripheral conversion of weaker ligands to stronger ones.
Adiol has both estrogenic and androgenic activities 6, 7 and is approximately 1,000 times less bioactive than E 2 and T, as indicated by cell-based ERLL and AR 12 bioassays, respectively. However, the circulating concentration of T is increasingly greater than that of E 2 as menopause approaches; thus, the relative contribution of Adiol to estrogenicity will increase, whereas its androgenic potential remains the same or decreases.
The strong overall correlation between circulating immunoreactive E 2 and bioactive estrogens (ERLL) in this study confirms that E 2 is the predominant circulating bioactive estrogen and contributes the most to total estrogenic bioactivity. Similarly, T is the predominate androgen 12 (Fig. 3) . These relationships support the concept that the estimates of serum ER and AR signal transduction are reasonable measures of total circulating bioactive sex steroids. The decreasing correlation of E 2 to ERLL and the increased correlation of Adiol to ERLL, when circulating E 2 concentrations decline and Adiol levels rise, confirm that the Adiol contribution to circulating estrogenicity increases when the concentration ratio of circulating E 2 to Adiol is sufficiently low.
Although the estrogenic bioactivity of Adiol is low compared with E 2 Vestimated to be 0.1% cross-bioactivity in vitro (Fig. 2 )Vits greater than 100-fold higher circulating concentration during the MT (10-1,015 pg/mL) and lower binding to SHBG compared with E 2 or T 13 enhances its biological importance. Circulating Adiol concentrations can reach 3,800 pM (1.1 ng/mL) in some women at or near menopause (Table 3) when E 2 concentrations are estimated to fall to 6 to 10 pM (G5-10 pg/mL). 2 This shift in the ratio from approximately 1:10 (E 2 /Adiol ) before the MT to 1:9100 (E 2 /Adiol) during and after menopause may result in a functional shift in the effective estrogenic potential of E 2 and Adiol. Such a biological effect has been suggested at the tissue level because Adiol has been shown to induce endometrial proliferation in anovulatory patients when circulating E 2 levels are low. 14 A wider range in circulating Adiol provides a more variable source of potential estrogenic support than E 2 , particularly when circulating E 2 levels are low (Table 3) . Because the circulating concentration of adrenal-derived Adiol is relatively constant compared with the day-to-day variations in ovarianderived E 2 , the Adiol effect will depend largely on the occurrence of low E 2 concentrations when Adiol levels are high. When circulating E 2 concentrations during and after menopause are reduced dramatically, 2 many women would probably exhibit symptoms of E 2 deficiency if there are no other sources of estrogenic support. Because some women do not exhibit such symptoms, it follows then that another source of estrogenicity probably exists.
The lower increase in Adione and T compared with Adiol suggests that there is a modest conversion of endogenous adrenal androgens to estrogens (or other metabolites) compared with the formation of Adiol during the MT (Table 3) . This observation also suggests one of two potential mechanisms for the greater increase in Adiol compared with T and Adione. One possibility is that a relatively low activity of peripheral 3A-hydroxysteroid dehydrogenase prevents the $5 to $4 conversion of nonaromatizable to aromatizable androgens and/or the lower activity of peripheral 17A-hydroxysteroid dehydrogenase that converts Adiol back to DHEA. Alternatively, the observed difference in adrenal secretory activity represented by a preferential increase in the adrenal C-19 $5 steroid pathway may arise from increased P450 c17 activity, thus increasing DHEAS and Adiol synthesis and secretion. Because some women do not manifest an increase in circulating adrenal steroids, particularly Adiol, this may partially explain some of the differences in symptoms and phenotypes that have been previously attributed to an E 2 -to-T balance. 15 Similarly, the failure of DHEA supplementation to have significant health benefits supports the concept that the marked benefits attributed to higher endogenous circulating DHEA levels 16, 17 are actually the effect of the increased Adiol that accompanies higher circulating DHEAS.
The present data also suggest a relatively constant adrenal contribution to circulating estrogenicity. Because both the immunoassay and ER signal transduction assay are relatively specific measures of E 2 and are based on the same standard, the ratio of ERLL divided by the total circulating (measured) E 2 provides an estimate of the portion of biologically active ER ligands that is a direct contribution of E 2 . If all of the circulating E 2 was bioactive and no other estrogens were in the system, then this ratio would be unity. The consistent finding of ratios between 0.75 and 0.76 when DHEAS concentrations are higher than 1 SD above the DHEAS mean indicates that there is a relatively constant portion of non-E 2 circulating estrogens that are contributing to total bioactive circulating ER ligands. However, this ratio drops to 0.64 and 0.49 when samples from the lowest group of DHEAScontaining samples are evaluated, indicating that the non-E 2 contribution to the ERLL measure of bioactive estrogens has fallen (Table 5 ). The decline is most probably due to the fall in circulating T and Adione, which are aromatized directly to E 2 and estrone, respectively, in peripheral tissues. This report has both weaknesses and strengths. First, as a descriptive study, it is largely observational and designed to address the single hypothesis that the rise in DHEAS may signal a rise in other adrenal steroids. However, the positive findings in this study are hypothesis-generating and promote several new and provocative concepts. Clearly, future studies will be needed to determine the relationship between changes in adrenal steroid hormone levels and the occurrence and severity of symptoms. This was simply beyond the scope of this investigation. Second, this study used relatively novel bioassays as experimental tools to provide additional insights into the endocrinology of the MT. Although these bioassays have not yet been validated in terms of providing clinically relevant information, they have been validated as useful laboratory research tools as demonstrated here and elsewhere. 12 As such, they can currently be used to provide support for new concepts that are biologically plausible and are therefore potentially clinically relevant. Currently, these assays are labor intensive, have not been broadly accepted as standardized methods, and remain largely research tools. The new data provided by these methods, however, can lead to additional and more thorough investigations in the future. Finally, the current study suggests but does not demonstrate that the changes in circulating adrenal steroids are a consequence of adrenal steroid hormone production rates. Ruling out changes in metabolism or clearance rate was beyond the scope of this study; however, there is no evidence to suggest that such changes occur during the MT and could have led to the range of circulating concentrations described here.
CONCLUSIONS
These data provide a novel potential explanation for the wide between-woman differences in phenotypes that are expressed during the MT by considering the contribution of circulating bioactive adrenal steroid hormone levels. This report shows that circulating Adiol, a weak bioactive estrogen and androgen, rises in concert with the rise in DHEAS during the MT to reach biologically effective concentrations. In addition, the current data provide a plausible alternative explanation for the strong association between higher endogenous DHEAS and superior administrative function 18 and the lack of efficacy of DHEA interventions. 19 Circulating Adiol rises to a range of concentrations that are more variable compared with the relatively consistent decline in circulating E 2 . Future studies are essential to determine the degree that the observed differences in Adiol concentrations correspond to and are associated with differences in the incidence and severity of symptoms and the trajectories of health outcomes. Indirect evidence supports the concept of an Adiol estrogenic role. A clinical effect of an adrenal contribution to circulating estrogenicity is suggested by the observation of a decline in non-E 2 components when Adiol levels are low. Furthermore, the positive correlation of higher levels of circulating Adiol to ER signal transduction suggest that the possibility that other estrogenic compounds could be involved was not explored. This shift is most evident when circulating E 2 concentrations are low. Together, these observations indicate that direct adrenal secretion of bioactive steroids and/or peripheral conversion of prohormones provide additional estrogenic support during and immediately after the MT.
